SUMMARY Methods: A multicentre randomized controlled trial was conducted to evaluate the efficacy of oral mesalazine (S-aminosalicylic acid) for the prevention of post-operatìve recurrence in 110 patients operated on for Crohn's disease by first ìntestìnal resection. Patients were randomly allocated to receive 2.4 gjday of mesalazine, or no treatment at alloThe protocol included colonoscopy with ileoscopy at 6 months and yearly thereafter. Recurrence was defined on the basis ofendoscopic criteria and classified as mild or severe. Results: The demographic and pre-trial characteristics were very similar in the two groups of patients. The cumulative proportion of recurrence at 6, 12 and 24 months was significantly lower in the mesalazine group than in untreated group (P = 0.002). At 24 months the cumulative proportions of endoscopic recurrence were 0.52 ± 0.12 (±S.E.M.) and 0.85 (± 0.07), respectively. At the same time the cumulative proportions of symptomatic recurrence were 0.18 ±0.09 and 0.41 ±0.09 (P = 0.006). The cumulative proportions of the severe recurrence was also significantly lower in the mesalazine group (0.17±0.09 vs. 0.38±0.09; P = 0.021). ConcIusions: The preliminary results of this study show that adrninistration of oral mesalazine soon after surgery is effective in preventing post-operatìve endoscopic recurrence in Crohn's disease over a 2-year periodoIt is estimated that this treatment preven ts 39% of all recurrences and 55% of the severe recurrences.

Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of postoperative recurrence of Crohn's disease. Aliment. Pharmacol. & Ther. 1994;8:35-43

LATELLA, GIOVANNI
1994

Abstract

SUMMARY Methods: A multicentre randomized controlled trial was conducted to evaluate the efficacy of oral mesalazine (S-aminosalicylic acid) for the prevention of post-operatìve recurrence in 110 patients operated on for Crohn's disease by first ìntestìnal resection. Patients were randomly allocated to receive 2.4 gjday of mesalazine, or no treatment at alloThe protocol included colonoscopy with ileoscopy at 6 months and yearly thereafter. Recurrence was defined on the basis ofendoscopic criteria and classified as mild or severe. Results: The demographic and pre-trial characteristics were very similar in the two groups of patients. The cumulative proportion of recurrence at 6, 12 and 24 months was significantly lower in the mesalazine group than in untreated group (P = 0.002). At 24 months the cumulative proportions of endoscopic recurrence were 0.52 ± 0.12 (±S.E.M.) and 0.85 (± 0.07), respectively. At the same time the cumulative proportions of symptomatic recurrence were 0.18 ±0.09 and 0.41 ±0.09 (P = 0.006). The cumulative proportions of the severe recurrence was also significantly lower in the mesalazine group (0.17±0.09 vs. 0.38±0.09; P = 0.021). ConcIusions: The preliminary results of this study show that adrninistration of oral mesalazine soon after surgery is effective in preventing post-operatìve endoscopic recurrence in Crohn's disease over a 2-year periodoIt is estimated that this treatment preven ts 39% of all recurrences and 55% of the severe recurrences.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11697/9493
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 197
  • ???jsp.display-item.citation.isi??? ND
social impact